AR062046A1 - Soluciones oftalmicas - Google Patents

Soluciones oftalmicas

Info

Publication number
AR062046A1
AR062046A1 ARP070103284A ARP070103284A AR062046A1 AR 062046 A1 AR062046 A1 AR 062046A1 AR P070103284 A ARP070103284 A AR P070103284A AR P070103284 A ARP070103284 A AR P070103284A AR 062046 A1 AR062046 A1 AR 062046A1
Authority
AR
Argentina
Prior art keywords
solutions
ophthalmic solutions
ophthalmic
artificial
eye
Prior art date
Application number
ARP070103284A
Other languages
English (en)
Inventor
Faour Joaquina
Pastini Ana
Original Assignee
Osmotica Pharmaceutical Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Pharmaceutical Argentina S A filed Critical Osmotica Pharmaceutical Argentina S A
Publication of AR062046A1 publication Critical patent/AR062046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Soluciones oftálmicas acuosas que contienen una combinación de ácido hialurónico o una sal farmacéuticamente aceptable del mismo, por ej. hialuronato de sodio y alcohol polivinílico. Estas soluciones poseen un efecto sinérgico en la viscosidad y proveen una mejora estadísticamente significativa sobre las formulaciones del arte previo. Las soluciones se utilizan como lágrima artificial para el tratamiento del ojo seco y molestias oculares y pueden administrarse siempre que sea recomendable el uso de lágrimas artificiales. Las soluciones también son adecuadas para utilizar como vehículo para drogas oftálmicas.
ARP070103284A 2006-07-25 2007-07-24 Soluciones oftalmicas AR062046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83308306P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
AR062046A1 true AR062046A1 (es) 2008-08-10

Family

ID=38863092

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103284A AR062046A1 (es) 2006-07-25 2007-07-24 Soluciones oftalmicas

Country Status (8)

Country Link
US (1) US20080050335A1 (es)
EP (1) EP2070518A2 (es)
KR (1) KR20090053892A (es)
AR (1) AR062046A1 (es)
BR (1) BRPI0714587A2 (es)
CA (1) CA2658646A1 (es)
MX (1) MX2009000885A (es)
WO (1) WO2008011836A2 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066901A1 (es) * 2007-05-18 2009-09-23 Alcon Mfg Ltd Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
WO2009074853A2 (en) * 2007-12-10 2009-06-18 Promed Research Centre Ophthalmic composition comprising phenylephrine
BRPI0909849A2 (pt) 2008-04-04 2015-10-06 Univ Utah Res Found éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los
CA2723954A1 (en) * 2008-05-19 2009-11-26 Alcon Research, Ltd. Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20110257125A1 (en) * 2008-10-02 2011-10-20 Rolf Schaefer Mucomimetic compositions and uses therefore
RU2011130552A (ru) * 2008-12-22 2013-01-27 Алькон Рисерч, Лтд. Композиции местных глазных растворов для доставки эффективных концентраций активного агента в задний сегмент глаза
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
EP2523669B1 (en) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN102869345B (zh) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 用于治疗眼内压增高的药物组合物
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
JP2013523828A (ja) * 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科用組成物のための保存剤の組み合わせ
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
KR101119610B1 (ko) * 2010-12-02 2012-03-06 한림제약(주) 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
JP6062917B2 (ja) 2011-03-23 2017-01-18 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション 泌尿器科の炎症の治療及び予防の方法
PL3192501T3 (pl) 2011-05-25 2020-11-02 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
WO2012163827A2 (en) * 2011-05-27 2012-12-06 Ratiopharm Gmbh Ophthalmic preparation comprising a pgf2alpha analogue
WO2012176865A1 (ja) * 2011-06-23 2012-12-27 参天製薬株式会社 ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液
EP2800573B1 (en) * 2012-01-08 2021-04-07 Medicure Technologies Ltd. Ophthalmic composition
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
ES2965828T3 (es) * 2012-09-12 2024-04-17 Novaliq Gmbh Composiciones de alcano semifluorado
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
CA2898644A1 (en) * 2013-01-24 2014-07-31 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US20140221309A1 (en) * 2013-02-01 2014-08-07 Allergan, Inc. Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcellulose
KR101412776B1 (ko) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
MX2015013234A (es) * 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
US9907750B2 (en) 2013-03-19 2018-03-06 Senju Pharmaceutical Co., Ltd. Two-layer separation-type eye drop containing squalane
PL3019177T3 (pl) 2013-07-10 2021-04-19 Matrix Biology Institute Kompozycje hialuronianu o dużej sprężystości i ich zastosowania
CN106459137B (zh) * 2014-05-01 2019-04-12 整体生物系统有限责任公司 用于治疗眼部病症的膜附着性自组装体系
CN104069118B (zh) * 2014-07-01 2016-08-24 武汉五景药业有限公司 滴眼液及其制备方法
ES2954412T3 (es) 2014-10-20 2023-11-22 Sentiss Pharma Private Ltd Solución oftálmica
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
RU2691412C2 (ru) * 2015-02-24 2019-06-13 Дзе Боард Оф Трастис Оф Дзе Юниверсити Оф Иллинойс Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
US10751337B2 (en) * 2015-02-24 2020-08-25 Ocugen, Inc. Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
EP3072503B1 (en) * 2015-03-26 2020-09-23 D.M.G. Italia Srl Ophthalmic composition for the corneal protection
CN106256351A (zh) * 2015-06-18 2016-12-28 江苏吉贝尔药业股份有限公司 盐酸奥洛他定凝胶滴眼液及其制备方法
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
CA2997372A1 (en) 2015-09-03 2017-03-09 The Administrators Of The Tulane Educational Fund Compositions and methods for multipurpose disinfection and sterilization solutions
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) * 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
CN108135926A (zh) 2015-09-24 2018-06-08 基质生物研究所 高弹性透明质酸组合物及其使用方法
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
ITUB20160876A1 (it) * 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo
AR108280A1 (es) * 2016-05-05 2018-08-08 Acraf Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
BR112019002967A2 (pt) * 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
KR101819709B1 (ko) 2017-01-13 2018-01-17 (주)아이엠디팜 설글리코타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 안구건조증의 예방 또는 치료용 약학 조성물
IT201700009786A1 (it) * 2017-01-30 2018-07-30 For Health Pharma S R L Sostituto lacrimale
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
JP2020523406A (ja) 2017-05-19 2020-08-06 オクジェン アイエヌシー． 眼科用組成物および使用方法
CN109276715A (zh) * 2017-07-20 2019-01-29 西安力邦医药科技有限责任公司 高保湿性的抗过敏鼻用药物组合物、其制备方法和应用
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US20210145862A1 (en) * 2018-04-18 2021-05-20 i.com medical GmbH High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces
CN110604812B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 一种含有重组人溶菌酶的人工泪液
CN110787126A (zh) * 2018-08-03 2020-02-14 武汉武药科技有限公司 一种盐酸莫西沙星眼用凝胶及其制备方法
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN110151690A (zh) * 2019-07-03 2019-08-23 上海美哈医药科技有限公司 一种眼部护理洗眼液及其制备方法
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
US11696910B2 (en) 2021-07-23 2023-07-11 Somerset Therapeutics, Llc Buffer-free, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
CN113952506B (zh) * 2021-09-26 2023-03-21 华南理工大学 一种仿生软骨表层修复水凝胶的制备方法
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
EP4309644A1 (en) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Preservative-free ophthalmic composition comprising an antiglaucoma agent

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679804A (en) * 1969-05-01 1972-07-25 Geigy Chem Corp Method for treating glaucoma with alkyl gallates
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
EP0323522A4 (en) 1987-07-07 1989-08-30 Santen Pharmaceutical Co Ltd ARTIFICIAL TEAR.
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
WO1991012808A1 (en) 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
JP3050898B2 (ja) 1990-07-06 2000-06-12 千寿製薬株式会社 水性医薬製剤
JP3310994B2 (ja) 1991-07-03 2002-08-05 電気化学工業株式会社 アレルギー治療剤
US5563171A (en) * 1993-11-05 1996-10-08 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
IT1273011B (it) * 1994-07-25 1997-07-01 Trhecnopharma S A Preparato oftalmico per l'uso come lacrima artificiale
US5674876A (en) * 1995-01-20 1997-10-07 Research Development Foundation ρ-heteroatom-substituted phenols and uses thereof
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
EP1050304A1 (en) * 1998-11-16 2000-11-08 Rohto Pharmaceutical Co., Ltd. Liquid ophthalmic preparations
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
RU2163123C2 (ru) 1999-05-26 2001-02-20 Уфимский научно-исследовательский институт глазных болезней Глазные капли
JP2002020279A (ja) 2000-06-30 2002-01-23 Taisho Pharmaceut Co Ltd 点眼液
US7074424B2 (en) * 2000-11-28 2006-07-11 Genzyme Corporation Polyalkylene glycol viscosity-enhancing polymeric formulations
PT1343474E (pt) * 2000-12-20 2010-04-19 Alcon Inc Solução de irrigação intra-ocular com características de fluidez aperfeiçoadas
JP3455852B2 (ja) 2000-12-26 2003-10-14 株式会社オフテクス 洗眼液組成物
PE20030263A1 (es) 2001-07-31 2003-04-17 Novartis Ag Composicion farmaceutica oftalmica
DE10161110A1 (de) 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
US7045121B2 (en) * 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
GB0130603D0 (en) * 2001-12-20 2002-02-06 Renaissance Healthcare Europ L Improvements in or relating to ophthalmic solutions
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
CA2839928C (en) * 2003-06-13 2016-10-04 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
JP2005187354A (ja) 2003-12-25 2005-07-14 Lion Corp 水性外用剤組成物
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
CA2565944C (en) * 2004-05-07 2011-07-19 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
US8288362B2 (en) * 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods

Also Published As

Publication number Publication date
KR20090053892A (ko) 2009-05-28
MX2009000885A (es) 2009-02-05
WO2008011836A3 (es) 2008-07-31
WO2008011836A2 (es) 2008-01-31
EP2070518A2 (en) 2009-06-17
CA2658646A1 (en) 2008-01-31
US20080050335A1 (en) 2008-02-28
BRPI0714587A2 (pt) 2013-05-07

Similar Documents

Publication Publication Date Title
AR062046A1 (es) Soluciones oftalmicas
AR122017A2 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
AR056254A1 (es) SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
AR049979A1 (es) Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BRPI0613401B8 (pt) composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
CU23367A3 (es) Formulación de moxifloxacino con sal común
AR047205A1 (es) Composiciones oftalmicas que contienen una combinacion sinergica de tres polimeros
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
NZ597626A (en) Bicyclic compound and use thereof for medical purposes
CL2009000625A1 (es) Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo.
AR066312A1 (es) Uso de glucoproteinas de mucina en combinacion con agentes terapeuticos para tratar lesiones epiteliales y trastornos por deterioro de la funcion de la mucina
BR0106913A (pt) Composições transparentes de limpeza em barra que são eficazes e não são irritantes para os olhos
AR072212A1 (es) Una composicion farmaceutica que comprende rebamipida
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal